Tracells

Company Overview

Snapshot

Founded in January 2024 by Maya Hanum and Yotam Harnik, Tracells operates with 1–10 employees. The company has raised $1 million across two funding rounds. In April 2024, Tracells secured a grant from the Israel Innovation Authority.

Business overview

Tracells specializes in developing non-invasive diagnostic testing solutions for inflammatory bowel diseases (IBD). The company's core technology utilizes advanced RNA transcriptomics and AI-driven classifiers to analyze RNA profiles from intestinal cells found in stool samples. This method aims to accurately diagnose IBD, assess inflammation severity and location, and predict therapy response, offering a convenient, home-based alternative to invasive procedures like endoscopies. Tracells operates within the Health Tech & Life Sciences sector, specifically targeting the pharmaceuticals and medical biotechnology markets with its diagnostic products.

Strategic signal

In March 2024, Tracells was highlighted as a pioneer in gastrointestinal diagnostics and therapeutics. This recognition signals the company's emerging influence and potential to innovate within the IBD diagnostic landscape, suggesting a strong market validation for its non-invasive approach and AI-driven RNA transcriptomics technology.

Company Intelligence Q&A

When was Tracells founded?

Tracells was founded in January 2024 by Maya Hanum and Yotam Harnik.

What is Tracells' core technology?

Tracells' core technology involves non-invasive diagnostic testing for inflammatory bowel diseases (IBD) using advanced RNA transcriptomics and AI-driven classifiers to analyze RNA profiles from intestinal cells in stool samples.

Has Tracells received any grants?

Yes, in April 2024, Tracells secured a grant from the Israel Innovation Authority.

What is the primary focus of Tracells' diagnostic tests?

Tracells' diagnostic tests are designed to accurately diagnose IBD, assess inflammation severity and location, and predict therapy response, aiming to replace invasive procedures with a home-based testing alternative.

How much capital has Tracells raised?

Tracells has raised $1 million across two funding rounds.